Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026